| 41 IPOs During the Week of February 1st, 2021 |
|---|
Issuer
Business | Deal
Size | Market Cap
at IPO | Price vs.
Midpoint | First Day
Return | Return
at 02/05 |
|---|
| Vor Biopharma (VOR) | $177M | $711M | 6% | +108% | +108% |
| Preclinical biotech developing cell therapies for hematological diseases. |
| Immunocore (IMCR) | $258M | $1,121M | 8% | +66% | +66% |
| Phase 3 biotech developing T cell therapies for cancer and other diseases. |
| Bolt Biotherapeutics (BOLT) | $230M | $757M | 18% | +61% | +61% |
| Phase 1/2 biotech developing targeted therapies for solid tumors. |
| Sana Biotechnology (SANA) | $588M | $4,928M | 16% | +40% | +56% |
| Preclinical biotech developing engineered cell therapies for multiple indications. |
| Lucira Health (LHDX) | $153M | $705M | 6% | +47% | +47% |
| Developing single-use test kits for COVID-19 and other infectious diseases. |
| Pharvaris (PHVS) | $165M | $668M | 11% | +45% | +45% |
| Dutch Phase 1 biotech developing oral small molecule therapies for rare diseases. |
| ON24 (ONTF) | $428M | $2,770M | 5% | +42% | +38% |
| Provides a B2B customer engagement platform supporting webinars and analytics. |
| TELUS International (TIXT) | $925M | $6,638M | 4% | +22% | +26% |
| Provides customer service outsourcing and digital IT services. |
| Sensei Biotherapeutics (SNSE) | $133M | $591M | 12% | -1% | +18% |
| Phase 2 biotech developing bacteriophage-based therapies for cancer. |
| Decarb. Plus Acq. II (DCRNU) | $350M | $428M | 0% | +13% | +15% |
| Fourth blank check company formed by Riverstone targeting businesses advancing global decarbonization. |
| Sustainable Dev. Acq. I (SDACU) | $275M | $344M | 0% | +12% | +12% |
| Blank check public benefit corporation formed by RRG and Capricorn Investment Group. |
| Atotech (ATC) | $498M | $3,345M | -17% | +13% | +12% |
| Carlyle-backed specialty chemicals company carved out of Total. |
| Fifth Wall Acquisition I (FWAA) | $300M | $375M | 0% | +11% | +11% |
| Blank check company targeting a real estate technology business. |
| Novus Capital Corp II (NXU.U) | $250M | $313M | 0% | +10% | +10% |
| Blank check company targeting businesses enabling smart technology evolution. |
| RMG Acquisition III (RMGCU) | $420M | $525M | 0% | +9% | +9% |
| Third blank check company formed by Riverside's James Carpenter and former Carlyle executive Robert Mancini. |
| G Squared Ascend I (GSQD.U) | $300M | $375M | 0% | +9% | +9% |
| Blank check company formed by G Squared targeting the tech sector. |
| Terns Pharmaceuticals (TERN) | $128M | $430M | 6% | +8% | +8% |
| Phase 2 biotech developing small molecule therapies for NASH. |
| Ark Global Acquisition (ARKIU) | $300M | $375M | 0% | +7% | +7% |
| Blank check company led by a former Groupon CEO and QIA fund manager targeting disruptive technology. |
| Atlas Crest Investment II (ACII.U) | $300M | $375M | 0% | +7% | +7% |
| Second blank check company formed by Moelis and Company. |
| CC Neuberger Holdings III (PRPC.U) | $350M | $488M | 0% | +7% | +7% |
| Third blank check company formed by CC Capital and Neuberger Berman. |
| Thunder Bridge III (TBCPU) | $360M | $459M | 0% | +6% | +6% |
| Third blank check company led by Gary Simanson targeting the fintech industry. |
| Angion Biomedica (ANGN) | $80M | $512M | 7% | +6% | +6% |
| Phase 3 biotech developing small molecule therapies for acute organ injuries. |
| Jaws Mustang Acquisition (JWSM.U) | $900M | $1,125M | 0% | +6% | +6% |
| Third blank check company led by Starwood Capital founder Barry Sternlicht. |
| Compute Health Acq. (CPUH.U) | $750M | $938M | 0% | +5% | +5% |
| Blank check company targeting the intersection of computation and healthcare. |
| Music Acquisition (TMAC.U) | $200M | $250M | 0% | +5% | +5% |
| Blank check company targeting the music sector. |
| Noble Rock Acquisition (NRACU) | $210M | $263M | 0% | +3% | +5% |
| Blank check company formed by Noble Rock Advisors targeting the software and tech-enabled services sectors. |
| HH&L Acquisition (HHLA.U) | $360M | $450M | 0% | +5% | +5% |
| Blank check company targeting the healthcare sector in Asia. |
| JOFF Fintech Acq. (JOFFU) | $360M | $450M | 0% | +4% | +4% |
| Blank check company targeting the financial services industry and FinTech. |
| COVA Acquisition (COVAU) | $261M | $326M | 0% | +4% | +4% |
| Blank check company formed by Crescent Cove Advisors targeting tech businesses in Southeast Asia. |
| Gaming & Hospitality Acq. (GHACU) | $175M | $227M | 0% | +4% | +4% |
| Blank check company formed by Affinity Gaming targeting the gaming and hospitality sectors. |
| Ares Acquisition (AAC.U) | $870M | $1,088M | 0% | +4% | +4% |
| Blank check company formed by Ares Management targeting a sustainable business. |
| Centricus Acquisition (CENHU) | $300M | $375M | 0% | +4% | +4% |
| UK-based blank check company led by former executives at Silversea Cruises and Deutsche Bank. |
| Itiquira Acquisition (ITQRU) | $200M | $250M | 0% | +3% | +4% |
| Blank check company targeting growth sectors in Brazil. |
| Thimble Point Acquisition (THMAU) | $240M | $300M | 0% | +4% | +4% |
| Blank check company targeting high-growth software and technology. |
| Kernel Group (KRNLU) | $265M | $331M | 0% | +4% | +3% |
| Blank check company targeting technology infrastructure sectors. |
| Quantum FinTech Acq. (QFTA.U) | $175M | $219M | 0% | +2% | +2% |
| Blank check company targeting businesses providing tech services to the financial sector. |
| Astrea Acquisition (ASAXU) | $150M | $192M | 0% | +2% | +2% |
| Blank check company targeting the hospitality and financial services sectors. |
| MDH Acquisition (MDH.U) | $240M | $300M | 0% | +2% | +2% |
| Blank check company formed by McLarty Diversified Holdings targeting businesses in the Heartland. |
| Altimar Acquisition II (ATMRU) | $300M | $375M | 0% | n/a | +0% |
| Second blank check company formed by HPS Investment Partners. |
| Evaxion Biotech (EVAX) | $30M | $214M | -9% | -1% | -1% |
| Danish Phase 1/2 biotech using AI to develop immuno-oncology therapies. |
| Landos Biopharma (LABP) | $100M | $650M | 0% | -25% | -31% |
| Phase 2 biotech developing oral small molecule therapies for autoimmune diseases. |
